Exisulind Prior to Radical Prostatectomy
Phase 2
Completed
- Conditions
- Prostatic Neoplasms
- Registration Number
- NCT00166478
- Lead Sponsor
- Mayo Clinic
- Brief Summary
This trial will compare no treatment to exisulind therapy. Patients enrolled on the treatment arm will begin treatment 4 weeks prior to the scheduled date of surgical removal of the prostate and will take 375 mg by mouth daily for the 4 weeks prior to radical prostatectomy. Participants will be followed for total of 2 months from the time of starting study drug.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 130
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method 4 week changes in apoptosis biomarkers
- Secondary Outcome Measures
Name Time Method 4 week changes in surrogate endpoint biomarkers
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Exisulind's induction of apoptosis in prostate cancer cells?
How does preoperative Exisulind compare to standard-of-care NSAIDs in reducing prostate cancer progression?
Which biomarkers correlate with response to Exisulind in patients with localized prostate neoplasms?
What are the adverse event profiles of Exisulind in preoperative prostate cancer management?
Are there combination therapies involving Exisulind and androgen receptor inhibitors for prostate cancer?
Trial Locations
- Locations (1)
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Mayo Clinic🇺🇸Rochester, Minnesota, United States